Display options
Cite
Decraecker M, Dutartre D, Hiriart JB, et al. Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use. Liver Int. 2021;doi: 10.1111/liv.15081.
Decraecker, M., Dutartre, D., Hiriart, J. B., Irles-Depé, M., Marraud des Grottes, H., Chermak, F., Foucher, J., Delamarre, A., & de Ledinghen, V. (2021). Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use. Liver international : official journal of the International Association for the Study of the Liver, . https://doi.org/10.1111/liv.15081
Decraecker, Marie, et al. "Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use." Liver international : official journal of the International Association for the Study of the Liver vol. (2021). doi: https://doi.org/10.1111/liv.15081
Decraecker M, Dutartre D, Hiriart JB, Irles-Depé M, Marraud des Grottes H, Chermak F, Foucher J, Delamarre A, de Ledinghen V. Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use. Liver Int. 2021 Oct 22; doi: 10.1111/liv.15081. Epub 2021 Oct 22. PMID: 34679242.
Copy Download .nbib Format: NLM
Share it on

Liver Int. 2021 Oct 22; doi: 10.1111/liv.15081. Epub 2021 Oct 22.

Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use.

Liver international : official journal of the International Association for the Study of the Liver

Marie Decraecker, Dan Dutartre, Jean-Baptiste Hiriart, Marie Irles-Depé, Hortense Marraud des Grottes, Faiza Chermak, Juliette Foucher, Adèle Delamarre, Victor de Ledinghen

Affiliations

  1. Hepatology unit, Hôpital Haut Lévêque, Bordeaux University Hospital, Bordeaux, France.
  2. INRIA, Talence, France.
  3. INSERM U1053, Bordeaux University, Bordeaux, France.

PMID: 34679242 DOI: 10.1111/liv.15081

Abstract

BACKGROUND & AIMS: The boundary between non-alcoholic (NAFLD) and alcohol-related liver disease (ALD) is based on alcohol consumption. However, metabolic syndrome and alcohol use frequently co-exist. The aim of this study was to determine prognostic factors of long-term morbidity and mortality in patients with NAFLD or ALD.

METHODS: From 2003 to 2016, all consecutive NAFLD or ALD patients were prospectively included in this cohort study. We evaluated overall survival, specific cause of mortality and occurrence of any complication. The primary endpoint was analysed by the Kaplan Meier method, secondary endpoints were estimated by Gray test method or logistic regressions. Factors independently associated with overall mortality and morbidity were identified by a multivariate Cox model.

RESULTS: A total of 3365 patients (1667 with ALD and 1698 with NAFLD) were included. Median follow-up was 54 months (range: 30-86) and 563 subjects died. In the overall population, overall mortality was higher in patients with ALD (HR: 10.1 [7.57-13.3]), and with weekly alcohol consumption >7 units (HR:1.66 [1.41-1.96]). Liver-related mortality was higher in patients with ALD (HR: 11 [7.27-16.5]). In the NAFLD group, weekly alcohol consumption >1 unit was associated with higher overall mortality (HR: 1.9 [1.1-3.4]), and weekly alcohol consumption >7 units was associated with higher overall morbidity (OR: 1.89 [1.61-2.21]). In the ALD group, the presence of metabolic syndrome was associated with higher overall (HR:1.27 [1.02-1.57]), and liver (HR: 1.47 [1.1-1.96]) mortalities, and overall (OR: 1.46 [1.14-1.88]), liver (OR: 1.46 [1.14-1.88]) morbidities.

CONCLUSION: In fatty liver diseases, light alcohol consumption and metabolic syndrome are prognosis cofactors.

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Keywords: alcohol; fibrosis; liver stiffness; metabolic syndrome; prognosis

References

  1. Nabi O, Lacombe K, Boursier J, Mathurin P, Zins M, Serfaty L. Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French Nationwide NASH-CO study. Gastroenterology. 2020;159(2):791-793.e2. - PubMed
  2. Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease. J Hepatol. 2018;68(2):251-267. - PubMed
  3. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. - PubMed
  4. Lai Y-J, Hu H-Y, Lee Y-L, et al. Frequency of alcohol consumption and risk of type 2 diabetes mellitus: a nationwide cohort study. Clin Nutr. 2019;38(3):1368-1372. - PubMed
  5. Hart CL, Morrison DS, Batty GD, Mitchell RJ, Smith GD. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010;340:c1240. - PubMed
  6. Younossi ZM, Stepanova M, Ong J, et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(8):1625-1633.e1. - PubMed
  7. Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet Lond Engl. 2018;391(10129):1513-1523. - PubMed
  8. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865-873. - PubMed
  9. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. - PubMed
  10. Younossi Z, Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology. 2016;150(8):1778-1785. - PubMed
  11. Chang Y, Cho YK, Kim Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69(1):64-75. - PubMed
  12. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554. - PubMed
  13. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatol Baltim Md. 2017;65(5):1557-1565. - PubMed
  14. Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019;70(2):273-283. - PubMed
  15. Cheng F, Cao H, Liu J, et al. Meta-analysis of the accuracy of transient elastography in measuring liver stiffness to diagnose esophageal varices in cirrhosis. Medicine (Baltimore). 2018;97(28):e11368. - PubMed
  16. Shili-Masmoudi S, Wong G-H, Hiriart J-B, et al. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int. 2020;40(3):581-589. - PubMed
  17. Shen Y, Wu S-D, Wu L, et al. The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis. Hepatol Int. 2019;13(5):560-572. - PubMed
  18. Naassila M. Alcool : un impact sur la santé, même à faibles doses [Éditorial]. Bull Epidemiol Hebd. 2019;(10-11):176-177. - PubMed
  19. Chang Y, Cho YK, Cho J, et al. Alcoholic and nonalcoholic fatty liver disease and liver-related mortality: a cohort study. Am J Gastroenterol. 2019;114(4):620-629. - PubMed
  20. Hajifathalian K, Sagvand BT, McCullough AJ. Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study. Hepatology. 2019;70(2):511-521. - PubMed
  21. Åberg F, Puukka P, Salomaa V, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology. 2020;71(3):835-848. - PubMed
  22. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443-457.e17. - PubMed
  23. Åberg F, Helenius-Hietala J, Puukka P, Färkkilä M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology. 2018;67(6):2141-2149. - PubMed
  24. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137(3):865-872. - PubMed
  25. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59(10):1410-1415. - PubMed
  26. Kanuri G, Landmann M, Priebs J, et al. Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice. Eur J Nutr. 2016;55(3):1153-1164. - PubMed
  27. Knott CS, Bell S, Britton A. The stability of baseline-defined categories of alcohol consumption during the adult life-course: a 28-year prospective cohort study. Addict Abingdon Engl. 2018;113(1):34-43. - PubMed
  28. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789-1795. - PubMed

Publication Types